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1. Definition and symptoms
Aortic stenosis is the most frequent cause of valvular intervention in the Western 
world and is increasing with age. Thus, awareness and basic knowledge about the 
management of aortic stenosis are important for a diverse spectrum of health-care 
providers. When a diagnosis of aortic stenosis is established, careful attention and 
management are warranted by several health-care providers including general 
practitioners, internists, geriatricians, anesthesiologists, thoracic surgeons, and 
imaging experts, besides cardiologists.
Symptoms of aortic stenosis are unspecific and often vague as the disease pro-
gression is typically slow. However, when patients finally present with symptoms 
related to a severe aortic gradient, it may require prompt action. Typically patients 
with aortic stenosis are limited by shortness of breath at exertion. Because adapta-
tion of lifestyle is common, it is crucial to recognize dyspnea due to aortic stenosis. 
Sometimes, a dramatic episode like syncope or cardiac arrhythmia occurs. Cardiac 
auscultation using a stethoscope is common in everyday practice throughout the 
health-care system, and the presence of a cardiac murmur may suggest an aortic 
stenosis. The same holds true for echocardiography (ECG), and signs of left ven-
tricular hypertrophy may lead to further investigations.
2. Diagnostic tools
2.1 Echocardiography
Echocardiography is the cornerstone in identification and follow-up of aortic 
stenosis. It visualizes the calcification of the aortic valve, and the Doppler technique 
quantifies the left ventricular outflow gradient [1]. The aortic valve area can be 
estimated by calculation or planimetry but must be considered in conjunction with 
the mean gradient, wall thickness, ejection fraction, ventricular dimension, valve 
calcification, and hemodynamic parameters at the time of exam.
Four classes of aortic stenosis can be described:
• High-gradient aortic stenosis. Here the valve area is <1 cm2, and the mean 
gradient is >40 mmHg. This is clearly a severe aortic stenosis regardless of 
ejection fraction.
• Low-flow, low-gradient aortic stenosis with reduced ejection fraction. 
Dobutamine echocardiography may be useful in these situations; an aortic 
valve area above 1 cm2 with flow normalization is suggestive of pseudos-
evere state.
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• Low-flow, low-gradient aortic stenosis with normal ejection fraction should be 
further evaluated if the area is <1 cm2, especially in the elderly with ventricular 
hypertrophy and diminished left chamber size. Other imaging tools using 
computerized tomography are beneficial to assess calcification score [2, 3].
• Normal-flow, low-gradient aortic stenosis with normal ejection fraction and 
mean gradient <40 mmHg even though the valve area is <1 cm2 is judged to be 
mild or moderate but not severe.
2.2 Exercise test
Evaluation of symptoms is related to the aortic stenosis that can be refined at 
an exercise test, typically ergometer bicycle test [4]. Using echocardiography at 
pharmacologically induced stress may reveal an increase in the pressure gradients 
[5]. Furthermore the response of ventricular function at exercise may give valuable 
information.
2.3 Miscellaneous imaging techniques
Multislice computerized tomography is nowadays an established method for 
quantification of valve calcification which is important in patients with low gradi-
ents. Furthermore computerized tomography offers excellent visualization of the 
aorta beyond the first part, the root. This is crucial in determination of preoperative 
anatomical assessment.
2.4 Laboratory markers
NT-proBNP is useful in follow-up of patients with aortic stenosis and is a 
complementary tool between intervals of echocardiography [6, 7].
3. Follow-up
Patients with aortic stenosis who are asymptomatic should undergo reevaluation 
every 6 months and should be asked to inform their physician the case of onset of 
symptoms. In mild to moderate aortic stenosis, evaluation every 3 years is reason-
able but more often if significant calcification is assessed.
4. Treatment
4.1 Aortic stenosis without symptoms
While symptomatic severe aortic stenosis should be recommended intervention 
as rule of thumb, patients without symptoms are controversial. Still, the presence 
of an unequivocal severe aortic stenosis has not been proven to benefit from early 
intervention [8, 9]. Patients with reduced ejection fraction deemed to be secondary 
to aortic stenosis should not be refrained from an intervention. It is also reasonable 
to recommend intervention in cases of exercise-induced symptoms attributed to 
stenosis [10]. In the careful evaluation of asymptomatic patients, the following 
factors can be taken into account: massive hypertrophy, abnormal longitudinal left 
ventricular function, and pulmonary hypertension.
3Introductory Chapter: Aortic Stenosis
DOI: http://dx.doi.org/10.5772/intechopen.86521
4.2 Pharmacological approach
Pharmacological therapy, including statins, has no impact on the disease 
progression in aortic stenosis. Nevertheless, concomitant hypertension should be 
treated. Patients who deteriorate into reduced ejection fraction should be subject to 
current heart failure optimization including beta-blocker, angiotensin-converting 
enzyme blocker/angiotensin receptor blocker, aldosterone receptor blocker, and 
rate/rhythm control if atrial fibrillation occurs.
4.3 Interventional approach
A patient with symptoms due to severe aortic stenosis should be evaluated for an 
interventional treatment. This is the only approach that will improve survival and 
relieve symptoms. In patients with an overall life expectancy of <12 months based 
on irreversible comorbidities, a conservative management is advocated.
The interventional mode is either surgical aortic valve replacement (SAVR) or 
transcatheter aortic valve implantation (TAVI). Based on the European Society 
Guidelines, a STS/EuroSCORE ≥4% favors TAVI and patients younger than 75 years 
based on limited long-term follow-up data of TAVI. In elderly patients, severe 
comorbidities (pulmonary or renal), considerable frailty, and those with restricted 
mobility, TAVI is preferred. In patients who previously underwent open-chest 
heart surgery, TAVI is advantageous due to adherent tissue which may complicate a 
second sternotomy.
4.4 Anatomical aspects: TAVI vs. SAVR
There are several factors that may be taken into account when choosing between 
TAVI and SAVR. A possible arterial approach is almost a prerequisite for TAVI, 
even though alternative routes may be an option. TAVI is the preferred method in 
patients who have sequele after chest radiation, porcelain aorta, risk of damage to 
grafting anastomosis following bypass surgery, and chest deformation. On the con-
trary, aortic root malfunction, thrombi in the aorta, and valve prosthesis mismatch 
are factors likely to favor TAVI.
SAVR should be performed in the case of concomitant need of other valve 
surgeries, aneurysm of the aorta, and septal hypertrophy requiring myectomy in 
hypertrophic cardiomyopathy.
4.5 Cardiac and extra-cardiac aspects: TAVI vs. SAVR
The individual risk should be assessed after careful evaluation and discussed 
between team members. The local resources and experience are important to be 
taken into account. In patients with high risk, TAVI is superior [11, 12]. Recently 
additional evidence points in the direction to favor TAVI in the majority of cases 
even in patients with low risk [13]. Notably, significant vascular complications, 
need of pacemaker implantation, and paravalvular regurgitation are more frequent 
for TAVI [14, 15]. SAVR is associated with more severe bleeding, acute renal fail-
ure, and atrial fibrillation. The risk of ischemic stroke seems to be similar [14, 15].
5. Future perspectives
The technical advancement of TAVI is expected to improve, and the increased 
volume is likely beneficial. However, long-term results over the decades are still 
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lacking. Complications, including the need of pacemaker implant, require attention 
and further innovation of techniques besides increased experience. Nevertheless, 
careful clinical judgment in the individual case is always warranted.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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